{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021833","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.433264+00:00","generated_at":"2026-06-22T09:49:16.238152+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAtla reports Q3 net loss $25.8M; cash $178.1M; BA3011 NSCLC shows 50% ORR in monotherapy","bullets":["Cash and cash equivalents $178.1M as of Sep 30, 2022, expected to fund operations into 2H24.","Net loss $25.8M for Q3 2022 vs $22.9M in Q3 2021; R&D expense increased to $19.8M.","BA3011 Phase 2 NSCLC: 4 PRs in monotherapy (ORR 50%) in non-squamous group; 1 CR in combination.","BA3011 UPS part 2 enrollment anticipated to start by year-end after FDA feedback; potential registrational path.","BA3071 Phase 1: first two cohorts completed without DLTs or SAEs; BA3182 IND on track by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021833","json":"https://secwatch.observer/filing/0000950170-22-021833.json","markdown":"https://secwatch.observer/filing/0000950170-22-021833.md","text":"https://secwatch.observer/filing/0000950170-22-021833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/0000950170-22-021833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/bcab-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:49:16.238152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"052afae50ceaae2abf0319a553a40bb9992bde77","claim":"BioAtla, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/0000950170-22-021833-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}